Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 11, 2023

BUY
$18.66 - $38.58 $19,369 - $40,046
1,038 Added 19.69%
6,310 $242,000
Q1 2023

May 02, 2023

SELL
$21.53 - $26.8 $28,591 - $35,590
-1,328 Reduced 20.12%
5,272 $122,000
Q4 2022

Feb 10, 2023

BUY
$18.63 - $27.35 $2,943 - $4,321
158 Added 2.45%
6,600 $173,000
Q3 2022

Nov 09, 2022

BUY
$17.51 - $23.37 $15,618 - $20,846
892 Added 16.07%
6,442 $127,000
Q2 2022

Aug 15, 2022

BUY
$12.59 - $18.8 $10,638 - $15,886
845 Added 17.96%
5,550 $97,000
Q1 2022

Jun 30, 2022

BUY
$12.02 - $16.69 $56,554 - $78,526
4,705 New
4,705 $77,000

Others Institutions Holding KDNY

About CHINOOK THERAPEUTICS, INC.


  • Ticker KDNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,896,300
  • Description
  • Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...
More about KDNY
Track This Portfolio

Track Amalgamated Bank Portfolio

Follow Amalgamated Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

News

Stay updated on Amalgamated Bank with notifications on news.